Summary & Overview
HCPCS Level II J2779: Ranibizumab (Susvimo) Intravitreal Implant Injection, 0.1 mg
HCPCS Level II code J2779 denotes the injection of ranibizumab via the Susvimo intravitreal implant (0.1 mg). This code captures a novel sustained-release delivery approach for anti-VEGF therapy used in retinal disease management and is important for accurate reporting of device-associated drug administration. Nationally, clear coding of implant-based biologic delivery affects billing consistency, payer coverage determinations, and utilization tracking for high-cost ophthalmic therapies.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical service represented by the code, the typical settings where the service is delivered, and which payers are commonly involved in coverage. The publication outlines expected benchmarks and policy-relevant details such as payer coverage considerations and coding practice implications for implant-based intravitreal drug delivery.
This summary provides a concise reference for clinicians, billing professionals, and policy analysts seeking to understand how HCPCS Level II code J2779 fits into current ophthalmic therapeutic delivery, payer engagement, and administrative reporting. Data not available in the input is noted where applicable in subsequent sections.
Billing Code Overview
HCPCS Level II code J2779 is for Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg. This code represents a single administration of ranibizumab delivered through a surgically implanted, refillable intravitreal implant designed to provide continuous ocular drug delivery.
Service Type: Intravitreal implant injection
Typical Site of Service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is a 70-year-old with neovascular (wet) age-related macular degeneration presenting for scheduled intravitreal therapy. The patient has previously undergone placement of the ranibizumab port delivery system (Susvimo) and now returns for in-office refill-exchange or administration of ranibizumab via the implant. Pre-procedure assessment includes review of visual acuity, intraocular pressure, ocular exam with slit lamp and dilated fundus exam, and confirmation of prior implant placement. The workflow: the patient checks in at an ambulatory ophthalmology clinic or specialty retina center; informed consent and medication reconciliation are confirmed; topical anesthesia and antisepsis are applied; the clinician performs the intravitreal implant refill-exchange or delivers ranibizumab through the implant per device-specific technique; post-procedure monitoring for intraocular pressure spike, endophthalmitis signs, and retinal detachment is performed for 30–60 minutes; discharge instructions and follow-up appointments are scheduled.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default reporting | Use when no specific modifier applies to the service. |
22 | Increased procedural services |